William Blair analyst Ryan Daniels has maintained their bullish stance on DOCS stock, giving a Buy rating on May 12.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ryan Daniels has given his Buy rating due to a combination of factors including Doximity’s strong financial performance and strategic positioning. The company reported a robust fiscal fourth quarter for 2025, with revenue increasing by 17% year-over-year, surpassing both the consensus expectations and its own guidance. Additionally, the adjusted EBITDA significantly exceeded forecasts, highlighting the company’s strong operating leverage.
Despite initial fiscal 2026 guidance coming in slightly below consensus, Daniels views the outlook as conservatively reasonable, considering macroeconomic uncertainties. The company has maintained strong visibility with a substantial portion of its subscription sales under contract. Furthermore, management’s confidence in doubling industry growth, supported by a competitive position and new product traction, reinforces the positive growth outlook. Daniels recommends accumulating shares on any market weakness, as the overall growth trajectory appears intact.
In another report released on May 12, Leerink Partners also maintained a Buy rating on the stock with a $78.00 price target.